BioAtla sought discussion with the FDA regarding the Phase 3 clinical trial design on August 8, 2025.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioAtla sought discussion with the FDA regarding the Phase 3 clinical trial design on August 8, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
- Helus Pharma is seeking review from the FDA for its drug candidate HLP003, led by company executive Eric So.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosi